Response to Aflibercept Therapy in Three Types of Choroidal Neovascular Membrane in Neovascular Age-Related Macular Degeneration: Real-Life Evidence in the Czech Republic

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F19%3AN0000146" target="_blank" >RIV/00064173:_____/19:N0000146 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/19:43918460 RIV/00216208:11150/19:10395539 RIV/00179906:_____/19:10395539 RIV/00843989:_____/19:E0107862 RIV/61988987:17110/19:A2102735

Výsledek na webu

<a href="https://doi.org/10.1155/2019/2635689" target="_blank" >https://doi.org/10.1155/2019/2635689</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/2019/2635689" target="_blank" >10.1155/2019/2635689</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Response to Aflibercept Therapy in Three Types of Choroidal Neovascular Membrane in Neovascular Age-Related Macular Degeneration: Real-Life Evidence in the Czech Republic

Popis výsledku v původním jazyce

Purpose. To present a cohort of treatment-naive patients with the neovascular form of age-related macular degeneration (nAMD) treated with aflibercept in a fixed regimen and evaluate the treatment response of three types of choroidal neovascular membrane (CNV)-occult (Type 1), classic (Type 2), and minimally classic (Type 4). Methods. This was a multicentre, prospective, observational consecutive case series study. Patients diagnosed with three types of CNV of nAMD were treated in a fixed regimen (3 injections every 4weeks, and then injections at 8week intervals). The follow-up period was 48weeks. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and spectral-domain optical coherence tomography (OCT). The measurements were taken at the baseline and then at 16, 32, and 48weeks. Results. The treatment-naive group was composed of 135 eyes of 135 patients in the study. 61 eyes had Type 1 lesions of CNV, 50 eyes had Type 2 lesions, and 24 eyes had Type 4 lesions. Mean baseline BCVA +/- SD for Type 1 lesions was 56.1 +/- 10.8 ETDRS letters, and then 62.2 +/- 12.9 letters, 61.2 +/- 13.7 letters, and 62.8 +/- 15.1 letters at 16, 32, and 48weeks, respectively. Mean baseline CRT +/- SD for Type 1 lesions was 442.4 +/- 194.9 mu m, and then 302.5 +/- 144.4 mu m, 299.7 +/- 128.5 mu m, and 277.7 +/- 106.5 mu m at 16, 32, and 48weeks, respectively. Mean baseline BCVA +/- SD for Type 2 lesions was 55.6 +/- 9.9 ETDRS letters, and then 62.5 +/- 11.1 letters, 60.7 +/- 13.0 letters, and 62.5 +/- 14.2 letters at 16, 32, and 48weeks, respectively. Mean baseline CRT +/- SD. For Type 4 lesions mean baseline BCVA +/- SD was 56.7 +/- 9.0 ETDRS letters, and then 59.1 +/- 10.6 letters, 59.5 +/- 11.4 letters, and 59.2 +/- 12.6 letters at 16, 32, and 48 weeks respectively. Mean baseline CRT +/- SD for Type 4 lesions was 492.1 +/- 187.0 mu m, and then 333.3 +/- 137.5 mu m, 354.4 +/- 175.0 mu m, and 326.7 +/- 122.4 mu m at 16, 32, and 48 weeks respectively. All these changes were statistically significant (p<0.005). Conclusions. The primary outcome of our study is that the treatment with aflibercept in nAMD patients led to statistically significant improvement in BCVA and to a decrease in CRT throughout the follow-up period in both occult and classic types of CNV. The minimally classic type of CNV demonstrated a poorer functional and anatomical response to treatment.

Název v anglickém jazyce

Response to Aflibercept Therapy in Three Types of Choroidal Neovascular Membrane in Neovascular Age-Related Macular Degeneration: Real-Life Evidence in the Czech Republic

Popis výsledku anglicky

Purpose. To present a cohort of treatment-naive patients with the neovascular form of age-related macular degeneration (nAMD) treated with aflibercept in a fixed regimen and evaluate the treatment response of three types of choroidal neovascular membrane (CNV)-occult (Type 1), classic (Type 2), and minimally classic (Type 4). Methods. This was a multicentre, prospective, observational consecutive case series study. Patients diagnosed with three types of CNV of nAMD were treated in a fixed regimen (3 injections every 4weeks, and then injections at 8week intervals). The follow-up period was 48weeks. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and spectral-domain optical coherence tomography (OCT). The measurements were taken at the baseline and then at 16, 32, and 48weeks. Results. The treatment-naive group was composed of 135 eyes of 135 patients in the study. 61 eyes had Type 1 lesions of CNV, 50 eyes had Type 2 lesions, and 24 eyes had Type 4 lesions. Mean baseline BCVA +/- SD for Type 1 lesions was 56.1 +/- 10.8 ETDRS letters, and then 62.2 +/- 12.9 letters, 61.2 +/- 13.7 letters, and 62.8 +/- 15.1 letters at 16, 32, and 48weeks, respectively. Mean baseline CRT +/- SD for Type 1 lesions was 442.4 +/- 194.9 mu m, and then 302.5 +/- 144.4 mu m, 299.7 +/- 128.5 mu m, and 277.7 +/- 106.5 mu m at 16, 32, and 48weeks, respectively. Mean baseline BCVA +/- SD for Type 2 lesions was 55.6 +/- 9.9 ETDRS letters, and then 62.5 +/- 11.1 letters, 60.7 +/- 13.0 letters, and 62.5 +/- 14.2 letters at 16, 32, and 48weeks, respectively. Mean baseline CRT +/- SD. For Type 4 lesions mean baseline BCVA +/- SD was 56.7 +/- 9.0 ETDRS letters, and then 59.1 +/- 10.6 letters, 59.5 +/- 11.4 letters, and 59.2 +/- 12.6 letters at 16, 32, and 48 weeks respectively. Mean baseline CRT +/- SD for Type 4 lesions was 492.1 +/- 187.0 mu m, and then 333.3 +/- 137.5 mu m, 354.4 +/- 175.0 mu m, and 326.7 +/- 122.4 mu m at 16, 32, and 48 weeks respectively. All these changes were statistically significant (p<0.005). Conclusions. The primary outcome of our study is that the treatment with aflibercept in nAMD patients led to statistically significant improvement in BCVA and to a decrease in CRT throughout the follow-up period in both occult and classic types of CNV. The minimally classic type of CNV demonstrated a poorer functional and anatomical response to treatment.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30207 - Ophthalmology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Ophthalmology

ISSN

2090-004X

e-ISSN

2090-0058

Svazek periodika

2019

Číslo periodika v rámci svazku

June

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

Article 2635689

Kód UT WoS článku

000474532800001

EID výsledku v databázi Scopus

2-s2.0-85068866199